Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
Analysis
Annabelle Lever makes a very strong argument for her case, and is ultimately convincing in her assertion that the degree of manipulation necessary to create a patentable gene warrants their continued patentable nature without ethical fears entering the picture. While it is important to respect life and the building blocks of life and to ensure that these building blocks do not suddenly fall under ridiculous legal restrictions or controls, it is also important to encourage progress in the new and still emerging area of gene creation and manipulation. Continuing to allow patents for genes and recognizing the ethical good that these patents can produce is important as brave new worlds of medical and technological capabilities are continuously invented, and limiting...
banking industry is not directly affected by the patentability of genes, however in the long-term there could be substantial impacts on profitability and in the type of business ventures banks can and should choose to back based on decisions in this regard. Banks providing funding capital for startup companies involved in gene creation are obviously impacted by whether or not genes can be patented, and must also take the ethicality of their investments and potential investments into account when making decisions. If gene patents were wholly unethical banks would be more limited in the scope of their activities.
PK = Deltagen Inc. PRXL = Parexel International Corp. Pvt1 = Quintiles Transnational Corp. (privately held) Industry = Biotechnology As of 2005 Source: Yahoo! Finance, April 29, 2007. Figure 1. Financial Performance: Charles River Laboratories vs. Deltagen Inc. And Parexel International Corp. - January 2002 to date. Source: Yahoo! Finance, April 29, 2007. Operating income for 2006 was reported by the company to be $188.2 million compared to $184.7 million for 2005 and its operating margin for 2006
I wonder if Europe is experiencing similar issues with the motivation system for its examiners. They could be pushed into demanding higher quality. However, compared to the drops in the U.S., the drops in Europe are not as staggering. Or the quality of patent applications is genuinely decreasing. The bigger issue as I see it is trying to determine if the decrease in patent rates is directly indicative of an
In Genentech, Hughes examines the remarkable rise of the Genentech company, which was an industry pioneer in the field of genetic engineering. The basic premise of Hughes’s book is that Genentech radically transformed biotechnology and even made a broader impact beyond the medical technology and science sectors. Themes Hughes addresses in Genentech include the business practices and processes needed to start a radical, innovative firm, particularly one with a business
This bill was sent to the U.S. Senate and set for vote mirroring a bill previously passed by the House during the Summer of 2003 which failed to pass the Senate because of vehement disagreement that was even "within the parties over the prohibition of therapeutic cloning.(National Legislation Concerning Human and Reproductive Cloning, 2004; paraphrased) As of the date of the report on legislation eight U.S. states had passed
Cooperative Strategy The criteria for successful Alliances in Emerging Country Economies Economic shifts and globalization caused by the development of emerging economies and the recent financial crisis have affected various industries. Firms must adapt appropriately to the new standard where time to market is shortened even with their shrinking capital bases and growing global competition. At a period when alliances and partnerships are fundamental, particular emerging economies are subject to become critical
Corn pollen had a high mortality rate (44% in 4 days) compared to those fed on and regular corn pollen showing no mortality. [Frontline/Nova] The allergenic potential of the transgenes that are used in GM products is a frightening problem. A noticeable case is that of Pioneer Hi-Bred INC, the international seed company that produced a genetically modified and enriched Soybean using the Brazilian nut gene. Fortunately, before the product